China approves AUGTYRO™ (Repotrectinib) for NTRK-positive solid tumors
Share
Zai Lab Limited (NASDAQ:ZLAB) announced on January 6, 2026, that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib).
This approval targets adult patients with advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
